Free tool
FAERS Monitor: Readyprep Chg
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207964 or its brand name (Readyprep Chg, Chlorhexidine Gluconate). Reports on generic versions are filed under their own applications.
Reports
66
Serious
37
56% of reports
Hospitalization
6
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash20
- skin reaction12
- erythema9
- pruritus4
- skin irritation4
- sepsis3
- burkholderia infection2
- eye irritation2
- hypersensitivity2
- pain2
- sputum culture positive2
- ageusia1
- alopecia1
- anosmia1
- application site discomfort1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 3 |
| 2017 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 19 |
| 2024 | 10 |
| 2025 | 12 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| burkholderia infection | 2 | 7876.6 | 1977.5 | 8,645 |
| sputum culture positive | 2 | 787.7 | 200.9 | 881 |
| skin reactionSignal | 12 | 271.7 | 162.8 | 2,970 |
| application site discomfort | 1 | 177.5 | 25.4 | 43 |
| skin irritationSignal | 4 | 27.8 | 10.8 | 79 |
| anosmia | 1 | 22.0 | 3.1 | 5 |
| rashSignal | 20 | 14.6 | 10.1 | 245 |
| erythemaSignal | 9 | 14.0 | 7.6 | 97 |
| ageusia | 1 | 12.8 | 1.8 | 2 |
| eye irritation | 2 | 11.1 | 2.8 | 10 |
| sepsisSignal | 3 | 8.6 | 2.8 | 13 |
| hypersensitivity | 2 | 3.4 | 0.9 | 1 |
| pruritusSignal | 4 | 3.3 | 1.3 | 4 |
| alopecia | 1 | 1.6 | 0.2 | 0 |
| pain | 2 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.